Strides Pharma Science Ltd

Stage 2 · Advancing · week 3Setup 6.4 ★ FairStrong +7.3

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. More about the company

₹1,100.6
+1.09% today
₹10,145 Cr · Mid cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
-10.7%
₹793.6 lo₹1,232.6 hi
10.7% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 3
1w13w26w
Week 3 — fresh breakout, verify structure
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
9.1%
200 DMA: ₹1,008.4 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.48x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
MA20 trending up · +4.7% vs MA50 +3.7%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+3.9%
3M
+1.8%
6M
+12.2%
YTD
+13.4%
1Y
+35.0%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
This stock ranks #36 of 77 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Ranks #31 of 61 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-12 → 2026-10-07
S2 74w
S2 16w
2023-07-122026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 74w → S3 4w → S4 13w → S1 2w → S4 3w → S1 10w → S2 8w → S3 6w → S2 11w → S3 7w → S4 3w → S2 16w → S3 8w → S2 2w current
Total tracked: 168 weeks across 14 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-07
Breakout Watch
Latest: 2026-09-22
Pullback Hunter
Latest: 2026-06-22
60 appearances in last 60 days. First seen: 2026-04-20.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S2
Wk 3 · Vol 0.48x
2026-10-06S2
Wk 2 · Vol 0.33x
2026-10-05S2
Wk 2 · Vol 0.26x
2026-10-01S2
Wk 2 · Vol 0.81x
2026-09-30S2
Wk 2 · Vol 1.09x
2026-09-29S2
Wk 2 · Vol 0.56x
2026-09-28S2
Wk 1 · Vol 0.28x
2026-09-25S2
Wk 1 · Vol 0.34x
2026-09-24S2
Wk 1 · Vol 0.30x
2026-09-23S2
Wk 1 · Vol 0.37x
2026-09-22S23→2
Wk 1 · Vol 0.70x
2026-09-21S3
Wk 8 · Vol 0.99x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹1,075.6
200 DMA
₹1,008.4
52W High
₹1,232.6
52W Low
₹793.6
5D Low
₹1,084.8
Resistance levels (recent highs)
20d High
₹1,232.6
60d High
₹1,232.6
120d High
₹1,232.6
250d High
₹1,232.6
Next resistance
+12.0%
to 20d High
Ask the Market AI about STARAsk →
P/E (TTM)
19.1
Forward 11.9
Earnings Growth (YoY)
+54.4%
Revenue +11.2%
ROE
+20.0%
Profit margin +11.4%
Dividend Yield
0.34%
P/B 3.9
About this companyHealth Care· Pharmaceuticals

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.